Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Case Report

Published on 18 Feb 2026

Germ-line exon 21 EGFR V831H mutation in advanced NSCLC resistance to almonertinib: a case report

in Cancer Molecular Targets and Therapeutics

Daxia Cai
Jian Lou
Yanyan Zhu
Yonghui Wang

Frontiers in Oncology

doi 10.3389/fonc.2026.1758636

229 views

Original Research

Published on 18 Feb 2026

Evexomostat (SDX-7320), a methionine aminopeptidase type 2 inhibitor, stimulates weight loss and inhibits obesity-accelerated tumor growth

in Cancer Molecular Targets and Therapeutics

Peter Cornelius
Benjamin A. Mayes
Andrew J. Dannenberg
Pierre J. Dufour
Sara Little
Douglas V. Guzior
John S. Petersen
James M. Shanahan
Bradley J. Carver

Frontiers in Oncology

doi 10.3389/fonc.2026.1751681

318 views

Case Report

Accepted on 17 Feb 2026

Case Report:furmonertinib dose escalation in heavily pretreated EGFR-mutant lung adenocarcinoma with diffuse brain metastases

in Cancer Molecular Targets and Therapeutics

Zian Jin
Changhong Dong
Kaiyuan Hui
Xiaodong Jiang

Frontiers in Oncology

Original Research

Published on 16 Feb 2026

RPL28 mediates sorafenib resistance in hepatocellular carcinoma by downregulating CDC6 expression

in Cancer Molecular Targets and Therapeutics

Yi Shi
Fangfang Chen
Yuanyuan Weng
Hang Zeng
Gang Chen

Frontiers in Oncology

doi 10.3389/fonc.2026.1741406

270 views

Original Research

Published on 16 Feb 2026

Characterization of skin adverse events associated with cetuximab: real-world insights from the two global pharmacovigilance databases of FAERS and VigiAccess

in Cancer Molecular Targets and Therapeutics

Chenwen Li
Yifei Gao
Min Guang
Huajuan Wu
Yunfei Li
Yaqing Lu
Yan Wei
Xueli Li
Li Yang

Frontiers in Oncology

doi 10.3389/fonc.2026.1768984

178 views

Original Research

Published on 12 Feb 2026

Early brain radiotherapy combined with third-generation EGFR-TKIs improves survival in EGFR-mutant NSCLC with synchronous brain metastases: a multi-center retrospective analysis

in Cancer Molecular Targets and Therapeutics

Yaru Kong
Yunchuan Sun
Li Xiao
Hongling Lu
Rui Wang
Yongchao Yu
Jianxi Zhou
Jiaju Zhang
Yingnan Zhou

Frontiers in Oncology

doi 10.3389/fonc.2026.1770066

422 views

Case Report

Accepted on 11 Feb 2026

Targeted and Immunotherapy Based on Tissue of Origin in Carcinoma of 1 Unknown Primary: A Two-Case Report and Literature Review

in Cancer Molecular Targets and Therapeutics

Mei Wang
DongYue Yan
Wen Sun
Jingshan Liang

Frontiers in Oncology

110 views

Review

Published on 11 Feb 2026

Honey and cancer: from traditional medicine to modern adjuvant therapy

in Cancer Molecular Targets and Therapeutics

Abdalsalam Kmail

Frontiers in Oncology

doi 10.3389/fonc.2026.1745285

575 views

Case Report

Accepted on 09 Feb 2026

Sequential Targeted Therapy in Synchronous Dual-Primary Lung Adenocarcinomas with EGFR and RET Alterations: A 5-Year Follow-Up Case Report

in Cancer Molecular Targets and Therapeutics

Yong-liang Niu
Ying Yang
Xiao-bao Teng
Ming-feng Han
DI-MING WANG

Frontiers in Oncology

Original Research

Published on 09 Feb 2026

Knowledge, attitudes, and decision-making regarding hyperbaric oxygen-assisted cancer treatment among related healthcare professionals

in Cancer Molecular Targets and Therapeutics

Cheng Zhou
Jia Zhang
Zhengze Dai
Dalin Fu
Yi Sun
Guopei Wu
Linsheng Chen
Xiao Lu

Frontiers in Oncology

doi 10.3389/fonc.2026.1732828

457 views

General Commentary

Accepted on 06 Feb 2026

Commentary: Novel mtDNA Methylation-Associated Prognostic Signatures in Colorectal Cancer

in Cancer Molecular Targets and Therapeutics

Xin Jiang
Xu Zhang
Maonan Wang

Frontiers in Oncology

161 views

Review

Accepted on 06 Feb 2026

The Structure and Functions of TRAF families and Recent Advances of TRAFs in Leukemia

in Cancer Molecular Targets and Therapeutics

Xudong Li
Le Gao
Meimei Yan
Ruochen Xu
Linping Xu
Yongping Song
Wei Li

Frontiers in Oncology

Original Research

Published on 06 Feb 2026

Research on the correlation and potential mechanism of PKCδ expression with efficacy and prognosis in diffuse large B-cell lymphoma

in Cancer Molecular Targets and Therapeutics

Xulu Zhao
Shan Li
Lin Zhu
Mei Wu
Xin Hu
Xiao Liang
Shanshan Wang
Aziguli Maihemaiti
Abulikemujiang Adili
Shujuan Wen

Frontiers in Oncology

doi 10.3389/fonc.2026.1690426

485 views

Original Research

Published on 06 Feb 2026

Multi-omics comprehensive analysis identified KIF22 and KRAS as highly synthetic lethal pairs for triple-negative breast cancer

in Cancer Molecular Targets and Therapeutics

Shichen Miao
Xiao Wang
Qiming Gu
Chengyu Bian
Rui Fan
Qichao Ni
Yi Wang
Zhigang Zhuang

Frontiers in Oncology

doi 10.3389/fonc.2026.1748954

667 views

Mini Review

Published on 04 Feb 2026

Glycosylated RNAs: discovery and implications in cancer biology

in Cancer Molecular Targets and Therapeutics

Shuai Tang
Ximo Wang
Fangmin Chen
Benyi Li

Frontiers in Oncology

doi 10.3389/fonc.2026.1719799

635 views

Correction

Published on 04 Feb 2026

Correction: SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance

in Cancer Molecular Targets and Therapeutics

Kunzhong Zhou
Yuewen Li
Weifang Wang
Yilin Chen
Bingyan Qian
Yiteng Liang
Hongmei Li
Ruiting Xu
Li Zhuang

Frontiers in Oncology

doi 10.3389/fonc.2026.1779304

353 views

Review

Accepted on 03 Feb 2026

Triple Metachronous Primary Malignancies: A Case Report of NGS-Guided Multidisciplinary Management and literature review

in Cancer Molecular Targets and Therapeutics

Xiangxue Li
Lihua Zhang
Xiaowei Wang
Jing Lv
Caiqi Liu
Siyi Zhang
Xiaoxuan Li
Jialin Song
Wensheng Qiu
Shufen Zhao

Frontiers in Oncology

Original Research

Published on 03 Feb 2026

Analysis on the efficacy and safety of chemotherapy combined with or without bevacizumab after CRS+HIPEC in patients with malignant peritoneal mesothelioma: a single-center retrospective study

in Cancer Molecular Targets and Therapeutics

Zhi-Ran Yang
Xin-Li Liang
Xin-Bao Li
Xin-Jing Zhang
He-Liang Wu
Yan-Dong Su
Yan Li
Song-Lin An

Frontiers in Oncology

doi 10.3389/fonc.2026.1733967

346 views

Original Research

Accepted on 02 Feb 2026

Peroxisomal Activity Drives Aggressive Bladder Cancer Phenotypes and Reveals Erythorbic Acid as a Potential Therapeutic Modulator

in Cancer Molecular Targets and Therapeutics

Qinghui Wu
Yu Zhou
Zhewen Ou
Housheng Fu
Fanchang Zeng
Daoyuan Li
Zhaocong Zheng
Fei Wang

Frontiers in Oncology

102 views

Review

Published on 30 Jan 2026

The methyltransferase METTL16 in digestive system cancers: functions and mechanisms

in Cancer Molecular Targets and Therapeutics

Jia Li
Yueyuan Bao
Fei Yao
Qingming Wu

Frontiers in Oncology

doi 10.3389/fonc.2026.1744928

418 views

Review

Accepted on 29 Jan 2026

Empowering Photodynamic Therapy With Artificial Intelligence: Current Trends and Future Directions

in Cancer Molecular Targets and Therapeutics

Avijit Paul
Marvin Xavierselvan
David Aebisher
Tomasz Kubrak
Dorota Bartusik-Aebisher
Srivalleesha Mallidi

Frontiers in Oncology

318 views

Original Research

Published on 29 Jan 2026

Identification of small molecule inhibitors targeting FGFR through molecular docking-based screening

in Cancer Molecular Targets and Therapeutics

Weibo Hou
Kun Liu
Ping Wang
Kefan Zheng
Qingran Kong
Xinyu Wang
Qi Zhao
Liang Cheng

Frontiers in Oncology

doi 10.3389/fonc.2026.1733391

754 views

Original Research

Published on 28 Jan 2026

Investigation of beetroot (Beta Vulgaris) extracts compared to staurosporine in human breast cancer cells: cellular functions in-vitro study

in Cancer Molecular Targets and Therapeutics

Suzan A. Abushal
Rokayya Sami
Nashi K. Alqahtani
Safa H. Qahl
Ahlam A. Harasani
Nouf A. Babteen
Hend F. Alharbi
Fahad Eid Albalawi
Fatimah Amer
Hajer A. Alfarteesh

Frontiers in Oncology

doi 10.3389/fonc.2026.1740274

541 views

Case Report

Published on 28 Jan 2026

Ceritinib efficacy in SMARCA4-deficient NSCLC harboring novel CTNND2 ALK/EML4-ALK fusion: case report

in Cancer Molecular Targets and Therapeutics

Zhigang Fu
Gengda Huang
Jian Xie
Li Luo
Qinqin Ren
Hong He
Yuan Wang
Jiexia Zhang

Frontiers in Oncology

doi 10.3389/fonc.2026.1680523

492 views

2,082 articles

articles

Germ-line exon 21 EGFR V831H mutation in advanced NSCLC resistance to almonertinib: a case report

Evexomostat (SDX-7320), a methionine aminopeptidase type 2 inhibitor, stimulates weight loss and inhibits obesity-accelerated tumor growth

Case Report:furmonertinib dose escalation in heavily pretreated EGFR-mutant lung adenocarcinoma with diffuse brain metastases

RPL28 mediates sorafenib resistance in hepatocellular carcinoma by downregulating CDC6 expression

Characterization of skin adverse events associated with cetuximab: real-world insights from the two global pharmacovigilance databases of FAERS and VigiAccess

Early brain radiotherapy combined with third-generation EGFR-TKIs improves survival in EGFR-mutant NSCLC with synchronous brain metastases: a multi-center retrospective analysis

Targeted and Immunotherapy Based on Tissue of Origin in Carcinoma of 1 Unknown Primary: A Two-Case Report and Literature Review

Honey and cancer: from traditional medicine to modern adjuvant therapy

Sequential Targeted Therapy in Synchronous Dual-Primary Lung Adenocarcinomas with EGFR and RET Alterations: A 5-Year Follow-Up Case Report

Knowledge, attitudes, and decision-making regarding hyperbaric oxygen-assisted cancer treatment among related healthcare professionals

Commentary: Novel mtDNA Methylation-Associated Prognostic Signatures in Colorectal Cancer

The Structure and Functions of TRAF families and Recent Advances of TRAFs in Leukemia

Research on the correlation and potential mechanism of PKCδ expression with efficacy and prognosis in diffuse large B-cell lymphoma

Multi-omics comprehensive analysis identified KIF22 and KRAS as highly synthetic lethal pairs for triple-negative breast cancer

Glycosylated RNAs: discovery and implications in cancer biology

Correction: SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance

Triple Metachronous Primary Malignancies: A Case Report of NGS-Guided Multidisciplinary Management and literature review

Analysis on the efficacy and safety of chemotherapy combined with or without bevacizumab after CRS+HIPEC in patients with malignant peritoneal mesothelioma: a single-center retrospective study

Peroxisomal Activity Drives Aggressive Bladder Cancer Phenotypes and Reveals Erythorbic Acid as a Potential Therapeutic Modulator

The methyltransferase METTL16 in digestive system cancers: functions and mechanisms

Empowering Photodynamic Therapy With Artificial Intelligence: Current Trends and Future Directions

Identification of small molecule inhibitors targeting FGFR through molecular docking-based screening

Investigation of beetroot (Beta Vulgaris) extracts compared to staurosporine in human breast cancer cells: cellular functions in-vitro study

Ceritinib efficacy in SMARCA4-deficient NSCLC harboring novel CTNND2 ALK/EML4-ALK fusion: case report